| 000 | 01846 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250517080849.0 | ||
| 264 | 0 | _c20161213 | |
| 008 | 201612s 0 0 eng d | ||
| 022 | _a1399-3003 | ||
| 024 | 7 |
_a10.1183/13993003.00850-2015 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _avan den Blink, Bernt | |
| 245 | 0 | 0 |
_aRecombinant human pentraxin-2 therapy in patients with idiopathic pulmonary fibrosis: safety, pharmacokinetics and exploratory efficacy. _h[electronic resource] |
| 260 |
_bThe European respiratory journal _cMar 2016 |
||
| 300 |
_a889-97 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aExercise Test |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHomeodomain Proteins _xadverse effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIdiopathic Pulmonary Fibrosis _xdrug therapy |
| 650 | 0 | 4 |
_aLung _xphysiopathology |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aNetherlands |
| 650 | 0 | 4 |
_aRecombinant Proteins _xadverse effects |
| 650 | 0 | 4 | _aRespiratory Function Tests |
| 650 | 0 | 4 |
_aSerum Amyloid P-Component _xadverse effects |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aUnited States |
| 700 | 1 | _aDillingh, Marlous R | |
| 700 | 1 | _aGinns, Leo C | |
| 700 | 1 | _aMorrison, Lake D | |
| 700 | 1 | _aMoerland, Matthijs | |
| 700 | 1 | _aWijsenbeek, Marlies | |
| 700 | 1 | _aTrehu, Elizabeth G | |
| 700 | 1 | _aBartholmai, Brian J | |
| 700 | 1 | _aBurggraaf, Jacobus | |
| 773 | 0 |
_tThe European respiratory journal _gvol. 47 _gno. 3 _gp. 889-97 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1183/13993003.00850-2015 _zAvailable from publisher's website |
| 999 |
_c25725946 _d25725946 |
||